The news from ESMO: An immunotherapy milestone, studying young-onset cancers, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
Category: ESMO
STAT+: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market….
STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced…
News from ESMO: An AstraZeneca win in bladder cancer, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates…
STAT+: Checkpoint inhibitor staves off disease progression in anal cancer trial
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients…
STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them…
STAT+: BMS immunotherapy boosts responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint…
STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK…
The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the…
Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
How do cancer drugs work? What makes biotech stocks go up? And why are venture…